+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioprocess Technology Market - Global Forecast 2026-2032- Product Image
Bioprocess Technology Market - Global Forecast 2026-2032- Product Image
Sale

Bioprocess Technology Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010892
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bioprocess Technology Market is projected to reach USD 51.52 Billion in 2026. It is expected to continue growing at a CAGR of 12.59%, reaching USD 105.23 Billion by 2032.

Bioprocess technology is becoming a strategic backbone of modern biomanufacturing, enabling the controlled production of biologics, vaccines, cell and gene therapies, enzymes, biosimilars, recombinant proteins, and advanced therapeutic modalities. The field spans upstream processing, downstream purification, cell culture, microbial fermentation, process analytical technology, single-use systems, automation, and quality-by-design practices. Demand is being shaped by the rising global burden of chronic and infectious diseases, wider use of biologic therapies, expanding biosimilar development, and the need for faster, more resilient manufacturing networks. Regulatory expectations around product quality, traceability, sterility assurance, and process validation are also intensifying the adoption of closed processing, continuous biomanufacturing, digital monitoring, and robust contamination control strategies. As life sciences organizations pursue greater productivity, flexibility, and sustainability, bioprocess technology is shifting from a specialized production function to a core enabler of therapeutic innovation, supply security, and healthcare preparedness.

Transformative Shifts in the Bioprocess Technology Landscape

The bioprocess technology landscape is undergoing a fundamental shift from stainless-steel, batch-centric production toward flexible, modular, digitally enabled, and increasingly continuous manufacturing models. Single-use bioprocessing has gained traction because it can reduce cleaning requirements, shorten changeover times, support multiproduct facilities, and lower cross-contamination risk when implemented with appropriate validation and supply-chain controls. Intensified upstream processes, high-cell-density cultures, perfusion systems, and improved media formulations are helping manufacturers improve productivity while reducing facility footprints. In downstream processing, chromatography innovation, membrane-based separations, viral clearance technologies, and automation are addressing persistent bottlenecks caused by higher upstream titers. At the same time, cell and gene therapies are pushing the sector toward smaller, patient-specific, and decentralized production models that require closed systems, rapid release testing, and highly controlled logistics. Sustainability is also reshaping procurement and facility design as manufacturers evaluate water use, energy consumption, solvent reduction, plastic waste management, and lifecycle performance across bioprocess operations.

Cumulative Impact of Artificial Intelligence on Bioprocess Technology

Artificial intelligence is increasingly influencing bioprocess technology by improving process development, monitoring, scale-up, deviation management, and decision-making. AI-enabled models can analyze high-dimensional bioprocess data from bioreactors, sensors, chromatography systems, laboratory information systems, and manufacturing execution platforms to identify relationships that are difficult to detect through conventional statistical methods. In upstream processing, machine learning supports media optimization, feeding strategy design, cell growth prediction, and early detection of process drift. In downstream operations, AI can help optimize purification parameters, predict column performance, improve yield consistency, and support real-time quality assessment. Digital twins and hybrid modeling are gaining importance because they combine mechanistic bioprocess knowledge with data-driven learning, allowing teams to simulate process behavior before implementing changes on the manufacturing floor. However, the cumulative impact of AI depends on data integrity, validated models, explainability, cybersecurity, and alignment with good manufacturing practice requirements. Organizations that establish strong data governance, interoperable systems, and cross-functional collaboration between bioprocess scientists, automation engineers, quality teams, and regulatory specialists are better positioned to capture measurable operational value from AI.

Key Regional Insights for Bioprocess Technology

Asia-Pacific is strengthening its role in bioprocess technology through expanding biopharmaceutical manufacturing capacity, government support for biotechnology, growing biosimilar activity, and rising demand for vaccines and advanced therapies. China, India, Japan, South Korea, Australia, and Southeast Asian economies are investing in biomanufacturing infrastructure, workforce development, and regulatory modernization, while regional contract manufacturing capabilities continue to mature. Europe is characterized by strong regulatory oversight, biosimilar expertise, advanced biomanufacturing research, and sustainability-focused production practices, supported by established quality frameworks for biologics, vaccines, and cell therapy manufacturing. North America remains a major center for biologics innovation, advanced therapy development, clinical-scale biomanufacturing, and adoption of automation, single-use platforms, and process analytical technology, supported by strong research ecosystems and established regulatory frameworks. Latin America is advancing bioprocess capabilities through vaccine production initiatives, biologics access programs, and local manufacturing partnerships, with Brazil and Mexico playing important roles in regional healthcare supply resilience. Africa is building bioprocess relevance through public health manufacturing initiatives, vaccine localization efforts, regional regulatory strengthening, and partnerships intended to reduce dependency on imported biologics and improve access to essential therapies. The Middle East is developing life sciences manufacturing as part of broader healthcare diversification strategies, with increasing attention to local vaccine capacity, biologics supply security, sterile manufacturing, and technology transfer.

Key Group Insights for Bioprocess Technology

NATO countries, while not a commercial market grouping, have relevance to bioprocess technology through biosecurity, medical preparedness, resilient supply chains, and strategic manufacturing capacity for vaccines, antidotes, diagnostics, and critical biologics used in public health emergencies. The G7 remains highly influential in bioprocess innovation, quality regulation, funding for biomedical research, pandemic preparedness, and advanced manufacturing adoption, with member countries shaping standards for biologics, vaccines, and emerging therapeutic platforms. BRICS economies are important because they combine large patient populations, expanding domestic pharmaceutical industries, and policy interest in local biomanufacturing, although infrastructure maturity, regulatory capacity, and technology access vary across members. The European Union continues to influence the bioprocess technology sector through harmonized regulatory standards, strong biologics and biosimilar expertise, sustainability policies, and support for advanced therapy manufacturing across its member states. ASEAN is emerging as a practical growth corridor for bioprocess technology due to improving healthcare infrastructure, rising pharmaceutical investment, and regional interest in vaccine and biologics manufacturing, with member economies seeking stronger technology transfer and quality systems. The GCC is emphasizing healthcare self-sufficiency and biotechnology as part of national diversification agendas, creating opportunities for bioprocess facilities, fill-finish operations, biologics logistics, and regional manufacturing partnerships.

Key Country Insights for Bioprocess Technology

China is rapidly expanding biomanufacturing capacity, biosimilar development, vaccine capabilities, and advanced therapy research, supported by domestic policy focus on biotechnology and improving regulatory alignment. The United States is a leading hub for bioprocess technology innovation, supported by extensive biologics research, advanced therapy pipelines, automation adoption, strong regulatory science capabilities, and mature clinical manufacturing infrastructure. Japan is recognized for high-quality biologics manufacturing, regenerative medicine regulation, advanced automation, and a strong emphasis on manufacturing consistency. India is a major contributor to vaccines, biosimilars, and cost-efficient biomanufacturing, with growing investment in process development, analytical capabilities, and quality systems. Germany combines engineering strength, biologics manufacturing expertise, strong process automation capabilities, and established biopharmaceutical production know-how. The United Kingdom remains influential in cell and gene therapy development, translational research, clinical trial infrastructure, and bioprocess skills development. Australia supports bioprocess technology through clinical research, biologics development, public health manufacturing initiatives, and regional supply resilience programs. France supports bioprocess technology through vaccine, biologics, and biomanufacturing initiatives, with attention to industrial modernization and health security. South Korea has become a prominent biomanufacturing center with strong biologics production capabilities, government-backed biotechnology programs, and increasing expertise in contract development and manufacturing. Italy and Spain contribute to European bioprocessing through pharmaceutical manufacturing, biosimilar activity, clinical research networks, and aseptic production capabilities. Canada is strengthening biomanufacturing through public health preparedness, vaccine capacity initiatives, and investment in life sciences infrastructure. Russia maintains activity in vaccine and biologics production with emphasis on domestic supply and biotechnology self-reliance. Brazil is central to Latin American bioprocess development due to its biologics demand, vaccine production history, public health manufacturing capabilities, and technology transfer experience. Mexico benefits from proximity to North American pharmaceutical supply chains and is gradually expanding its role in manufacturing, clinical supply, sterile operations, and healthcare access.

Actionable Recommendations for Bioprocess Technology Leaders

Industry leaders should prioritize flexible bioprocess architectures that combine single-use technologies, closed processing, modular facility design, and scalable automation to support faster product transitions and multiproduct operations. Strengthening digital maturity is essential, including investment in process analytical technology, real-time data capture, validated AI models, electronic batch records, and interoperable manufacturing systems. Organizations should address downstream bottlenecks early in process development by optimizing purification strategies, resin utilization, membrane performance, and viral clearance design. To improve resilience, leaders should diversify critical suppliers for single-use components, culture media, resins, filters, sensors, and sterile connectors while maintaining rigorous supplier qualification and change-control processes. Workforce development should focus on bioprocess engineering, data science, automation, aseptic operations, quality systems, and regulatory readiness. Sustainability should be embedded through lifecycle assessment, waste reduction, water and energy efficiency, and responsible materials management. For advanced therapies, leaders should design closed, traceable, and patient-centric manufacturing workflows that reduce manual intervention and support reliable chain-of-identity and chain-of-custody controls.

Research Methodology

This executive summary is developed using a structured secondary research approach centered on verified public-domain and industry-recognized sources, including regulatory guidance, scientific literature, public health agency materials, patent and standards references, clinical development trends, manufacturing technology publications, pharmacopeial standards, and government biotechnology initiatives. The analysis emphasizes triangulation across multiple credible sources to identify consistent patterns in bioprocess technology adoption, regional manufacturing development, artificial intelligence integration, regulatory expectations, and operational best practices. Qualitative assessment focuses on technology maturity, manufacturing use cases, policy direction, supply-chain considerations, and therapeutic application areas. The methodology deliberately excludes market sizing, market share calculations, financial forecasting, and speculative estimates, ensuring the summary remains focused on validated industry dynamics, evidence-based technology trends, and strategic implications for stakeholders.

Conclusion

Bioprocess technology is advancing rapidly as biologics, vaccines, biosimilars, and advanced therapies demand faster, cleaner, more flexible, and more data-driven manufacturing systems. The convergence of single-use platforms, continuous processing, process analytical technology, AI-enabled modeling, closed manufacturing, and sustainability-focused operations is redefining how therapeutic products are developed and produced. Regional and country-level initiatives are reinforcing the importance of local biomanufacturing capacity, quality infrastructure, regulatory readiness, and resilient supply chains. Organizations that combine scientific rigor with digital transformation, regulatory discipline, supplier resilience, and skilled talent development will be best positioned to improve productivity, accelerate technology transfer, and maintain consistent product quality in an increasingly complex biopharmaceutical environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Bioprocess Technology Market, by Process Mode
7.1. Introduction
7.2. Batch
7.3. Continuous
7.3.1. Chemostat
7.3.2. Perfusion
7.4. Fed Batch
7.4.1. Exponential Fed
7.4.2. Pulse Fed
8. Bioprocess Technology Market, by Material
8.1. Introduction
8.2. Hybrid
8.3. Single-Use
8.3.1. Rocking Motion Bioreactor
8.3.2. Stirred-Tank Single-Use
8.3.3. Wave Bioreactor
8.4. Stainless Steel
9. Bioprocess Technology Market, by Scale
9.1. Introduction
9.2. Clinical Scale
9.3. Commercial Scale
9.4. Pilot Scale
10. Bioprocess Technology Market, by Application
10.1. Introduction
10.2. Cell Therapy And Regenerative Medicine
10.2.1. CAR-T Therapy
10.2.2. Stem Cell Therapy
10.3. Monoclonal Antibody Production
10.4. Recombinant Protein Production
10.5. Vaccine Production
10.5.1. mRNA Vaccine
10.5.2. Subunit Vaccine
11. Bioprocess Technology Market, by End User
11.1. Introduction
11.2. Academic And Research Institutes
11.3. Biopharmaceutical Companies
11.4. Contract Manufacturing Organizations
12. Bioprocess Technology Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Bioprocess Technology Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Bioprocess Technology Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ABEC, Inc.
16.2. AdvantaPure
16.3. Agilent Technologies, Inc.
16.4. Avantor, Inc.
16.5. Bio-Rad Laboratories, Inc.
16.6. CellGenix GmbH
16.7. Colder Products Company
16.8. Corning Incorporated
16.9. Cytiva
16.10. Danaher Corporation
16.11. Eppendorf SE
16.12. GEA Group AG
16.13. Getinge AB
16.14. Hamilton Company
16.15. Lonza Group AG
16.16. Meissner Filtration Products, Inc.
16.17. Merck KGaA
16.18. PBS Biotech, Inc.
16.19. Repligen Corporation
16.20. SaniSure
16.21. Sartorius AG
16.22. Takara Bio Inc.
16.23. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL BIOPROCESS TECHNOLOGY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOPROCESS TECHNOLOGY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOPROCESS TECHNOLOGY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOPROCESS TECHNOLOGY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOPROCESS TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL BIOPROCESS TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BIOPROCESS TECHNOLOGY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CONTINUOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CONTINUOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CONTINUOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CHEMOSTAT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CHEMOSTAT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CHEMOSTAT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PERFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PERFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PERFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL FED BATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL FED BATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL FED BATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL EXPONENTIAL FED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL EXPONENTIAL FED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL EXPONENTIAL FED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PULSE FED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PULSE FED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PULSE FED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL HYBRID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL HYBRID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL HYBRID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SINGLE-USE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SINGLE-USE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SINGLE-USE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ROCKING MOTION BIOREACTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ROCKING MOTION BIOREACTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ROCKING MOTION BIOREACTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL STIRRED-TANK SINGLE-USE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL STIRRED-TANK SINGLE-USE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL STIRRED-TANK SINGLE-USE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL WAVE BIOREACTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL WAVE BIOREACTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL WAVE BIOREACTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL STAINLESS STEEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL STAINLESS STEEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL STAINLESS STEEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CLINICAL SCALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CLINICAL SCALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CLINICAL SCALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL COMMERCIAL SCALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL COMMERCIAL SCALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COMMERCIAL SCALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PILOT SCALE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PILOT SCALE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PILOT SCALE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CELL THERAPY AND REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CELL THERAPY AND REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CELL THERAPY AND REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL MONOCLONAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MONOCLONAL ANTIBODY PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MONOCLONAL ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RECOMBINANT PROTEIN PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RECOMBINANT PROTEIN PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RECOMBINANT PROTEIN PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL VACCINE PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL VACCINE PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL VACCINE PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MRNA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MRNA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MRNA VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 105. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 106. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 107. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 108. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 110. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 111. EUROPE BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 136. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 137. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 138. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 139. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 140. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 141. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 142. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 144. AFRICA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 159. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 160. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 161. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 162. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 163. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 164. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 165. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 166. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 167. NATO BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 170. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 171. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 172. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 173. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 174. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 175. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 176. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 177. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 178. G7 BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 181. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 182. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 183. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 184. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 185. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 186. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 188. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 189. BRICS BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 203. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 204. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 205. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 206. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 207. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 208. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 209. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 210. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 211. ASEAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 214. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 215. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 216. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 217. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 218. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 219. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 221. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 222. GCC BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GLOBAL BIOPROCESS TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 224. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 226. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 227. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 228. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 229. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 230. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 231. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 232. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 233. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 234. CHINA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 248. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 249. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 250. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 251. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 252. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 253. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 254. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 255. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 256. JAPAN BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 259. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 260. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 261. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 262. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 263. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 264. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 265. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 266. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 267. INDIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 270. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 271. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 272. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 273. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 274. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 275. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 276. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 277. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 278. GERMANY BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 300. AUSTRALIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 301. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 303. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 305. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 306. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 307. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 308. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 309. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 310. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 311. FRANCE BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 316. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 322. SOUTH KOREA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 325. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 326. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 327. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 328. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 329. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 330. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 331. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 332. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 333. ITALY BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 336. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 337. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 338. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 339. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 340. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 341. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 342. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 343. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 344. CANADA BIOPROCESS TECHNOLOGY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 345. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY PROCESS MODE, 2017-2032 (USD MILLION)
TABLE 347. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CONTINUOUS, 2017-2032 (USD MILLION)
TABLE 348. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY FED BATCH, 2017-2032 (USD MILLION)
TABLE 349. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY MATERIAL, 2017-2032 (USD MILLION)
TABLE 350. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SINGLE-USE, 2017-2032 (USD MILLION)
TABLE 351. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY SCALE, 2017-2032 (USD MILLION)
TABLE 352. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 353. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY CELL THERAPY AND REGENERATIVE MEDICINE, 2017-2032 (USD MILLION)
TABLE 354. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE, BY VACCINE PRODUCTION, 2017-2032 (USD MILLION)
TABLE 355. RUSSIA BIOPROCESS TECHNOLOGY MARKET SIZE

Companies Mentioned

  • ABEC, Inc.
  • AdvantaPure
  • Agilent Technologies, Inc.
  • Avantor, Inc.
  • Bio-Rad Laboratories, Inc.
  • CellGenix GmbH
  • Colder Products Company
  • Corning Incorporated
  • Cytiva
  • Danaher Corporation
  • Eppendorf SE
  • GEA Group AG
  • Getinge AB
  • Hamilton Company
  • Lonza Group AG
  • Meissner Filtration Products, Inc.
  • Merck KGaA
  • PBS Biotech, Inc.
  • Repligen Corporation
  • SaniSure
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 51.52 Billion
Forecasted Market Value ( USD ) by 2032 $ 105.23 Billion
Compound Annual Growth Rate12.5%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Bioprocess Technology Market Report 2026 - Product Image

Bioprocess Technology Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bioprocess Technology Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Bioprocess Technology Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Bioprocess Technology Market 2025-2029 - Product Image

Bioprocess Technology Market 2025-2029

  • Report
  • 296 Pages
  • Global
From
Bioprocess Validation Market - Global Forecast 2026-2032 - Product Image

Bioprocess Validation Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Single-use Bioprocessing Market - Global Forecast 2026-2032 - Product Image

Single-use Bioprocessing Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.